| dc.contributor.author | Bajoria, Sakshi | |
| dc.contributor.author | Kaur, Kawaljit | |
| dc.contributor.author | Kumru, Ozan S | |
| dc.contributor.author | Van Slyke, Greta | |
| dc.contributor.author | Doering, Jennifer | |
| dc.contributor.author | Novak, Hayley | |
| dc.contributor.author | Rodriguez Aponte, Sergio A | |
| dc.contributor.author | Dalvie, Neil C | |
| dc.contributor.author | Naranjo, Christopher A | |
| dc.contributor.author | Johnston, Ryan S | |
| dc.contributor.author | Silverman, Judith Maxwell | |
| dc.contributor.author | Kleanthous, Harry | |
| dc.contributor.author | Love, J Christopher | |
| dc.contributor.author | Mantis, Nicholas J | |
| dc.contributor.author | Joshi, Sangeeta B | |
| dc.contributor.author | Volkin, David B | |
| dc.date.accessioned | 2025-11-17T22:17:42Z | |
| dc.date.available | 2025-11-17T22:17:42Z | |
| dc.date.issued | 2022-06-06 | |
| dc.identifier.uri | https://hdl.handle.net/1721.1/163742 | |
| dc.description.abstract | Low-cost, refrigerator-stable COVID-19 vaccines will facilitate global access and improve vaccine coverage
in low- and middle-income countries. To this end, subunit-based approaches targeting the receptorbinding domain (RBD) of SARS-CoV-2 Spike protein remain attractive. Antibodies against RBD neutralize
SARS-CoV-2 by blocking viral attachment to the host cell receptor, ACE2. Here, a yeast-produced recombinant RBD antigen (RBD-L452K-F490W or RBD-J) was formulated with various combinations of aluminum-salt (Alhydrogel®, AH; AdjuPhos®, AP) and CpG 1018 adjuvants. We assessed the effect of antigenadjuvant interactions on the stability and mouse immunogenicity of various RBD-J preparations. While
RBD-J was 50% adsorbed to AH and <15% to AP, addition of CpG resulted in complete AH binding, yet no
improvement in AP adsorption. ACE2 competition ELISA analyses of formulated RBD-J stored at varying
temperatures (4, 25, 37°C) revealed that RBD-J was destabilized by AH, an effect exacerbated by CpG. DSC
studies demonstrated that aluminum-salt and CpG adjuvants decrease the conformational stability of
RBD-J and suggest a direct CpG-RBD-J interaction. Although AH+CpG-adjuvanted RBD-J was the least
stable in vitro, the formulation was most potent at eliciting SARS-CoV-2 pseudovirus neutralizing antibodies in mice. In contrast, RBD-J formulated with AP+CpG showed minimal antigen-adjuvant interactions, a better stability profile, but suboptimal immune responses. Interestingly, the loss of in vivo potency
associated with heat-stressed RBD-J formulated with AH+CpG after one dose was abrogated by a booster.
Our findings highlight the importance of elucidating the key interrelationships between antigen-adjuvant
interactions, storage stability, and in vivo performance to enable successful formulation development of
stable and efficacious subunit vaccines. | en_US |
| dc.language.iso | en | |
| dc.publisher | Informa UK Limited | en_US |
| dc.relation.isversionof | 10.1080/21645515.2022.2079346 | en_US |
| dc.rights | Creative Commons Attribution-NonCommercial-NoDerivatives | en_US |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
| dc.source | Informa UK Limited | en_US |
| dc.title | Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Bajoria, S., Kaur, K., Kumru, O. S., Van Slyke, G., Doering, J., Novak, H., … Volkin, D. B. (2022). Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. Human Vaccines & Immunotherapeutics, 18(5). | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biological Engineering | en_US |
| dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Chemical Engineering | en_US |
| dc.relation.journal | Human Vaccines & Immunotherapeutics | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dc.date.updated | 2025-11-07T22:04:05Z | |
| dspace.orderedauthors | Bajoria, S; Kaur, K; Kumru, OS; Van Slyke, G; Doering, J; Novak, H; Rodriguez Aponte, SA; Dalvie, NC; Naranjo, CA; Johnston, RS; Silverman, JM; Kleanthous, H; Love, JC; Mantis, NJ; Joshi, SB; Volkin, DB | en_US |
| dspace.date.submission | 2025-11-07T22:04:07Z | |
| mit.journal.volume | 18 | en_US |
| mit.journal.issue | 5 | en_US |
| mit.license | PUBLISHER_CC | |
| mit.metadata.status | Authority Work and Publication Information Needed | en_US |